|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University Health Network, Toronto |
|---|---|
| Information provided by: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT00145964 |
Purpose
Primary biliary cirrhosis (PBC) is a disease of the liver, which predominantly affects women. It causes slowly progressive liver disease, which eventually causes liver failure, requiring a liver transplant. Several different studies of large patient cohorts indicate that the cause of this disease is likely due to a combination of factors including genetic and environmental. PBC is associated with several other "autoimmune diseases" - recently a gene has been identified to be abnormal in individuals with another autoimmune liver disease, namely rheumatoid arthritis. This gene usually tells the body when to switch off an immune response. This study plans to identify whether individuals diagnosed with PBC have a similar abnormality in this gene called protein Tyrosine Phosphatase.
| Condition |
|---|
|
Liver Cirrhosis, Biliary Biliary Cirrhosis, Primary |
| Study Type: | Observational |
| Study Design: | Cross-Sectional, Defined Population, Prospective Study |
| Official Title: | Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC) |
| Estimated Enrollment: | 500 |
| Study Start Date: | August 2004 |
Very recently, a single nucleotide polymorphism (SNP) in the PTPN22 gene encoding the Lyp (lymphoid-specific phosphatase) PTP has been shown to be associated with susceptibility to rheumatoid arthritis (RA) and Type 1 diabetes (T1D)4,5. These data are consistent with the known role for Lyp in suppressing T cell activation and with data showing T cell activation (and potentially autoreactivity) to be increased by the RA and T1D-associated PTPN22 variant. The PTPN22 risk allele has also been recently implicated in Grave’s disease and as such appears to represent a susceptibility allele for many autoimmune diseases. As a number of these conditions (RA, T1D etc.) frequently occur within members of PBC families, this PTPN22 variant is very likely to also be involved in PBC, a possibility we will directly investigate in this pilot study. The aim of this study is to analyze the frequency of a specific PTPN22 polymorphism in patients with PBC.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
- AMA negative PBC
Contacts and Locations| Contact: Catalina Coltescu | 416-603-5832 |
| Canada, Ontario | |
| Liver Clinic, Toronto Western Hospital, UHN. | Recruiting |
| Toronto, Ontario, Canada, M5T 2S8 | |
| Contact: Jenny (E.J.L.) Heathcote, MD 416-603-5914 | |
| Principal Investigator: E. J. L. Heathcote, M.D. | |
| Principal Investigator: | E.J.L (Jenny) Heathcote, MD | UHN - Toronto Western Hospital, University of Toronto |
More Information
| Study ID Numbers: | 04-0461-AE |
| Study First Received: | September 2, 2005 |
| Last Updated: | November 28, 2005 |
| ClinicalTrials.gov Identifier: | NCT00145964 |
| Health Authority: | Canada: Health Canada |
|
Biliary Cirrhosis, Primary genes autoimmune disease |
|
Biliary cirrhosis Liver Diseases Digestive System Diseases Cholestasis, Intrahepatic Autoimmune Diseases Bile Duct Diseases |
Cholestasis Fibrosis Biliary Tract Diseases Liver Cirrhosis Primary biliary cirrhosis Liver Cirrhosis, Biliary |
|
Pathologic Processes |
